Possible contribution of taurine to distorted glucagon secretion in intra-islet insulin deficiency: a metabolome analysis using a novel α-cell model of insulin-deficient diabetes.
Glycemic instability is a serious problem in patients with insulin-deficient diabetes, and it may be due in part to abnormal endogenous glucagon secretion. However, the intracellular metabolic mechanism(s) involved in the aberrant glucagon response under the condition of insulin deficiency has not yet been elucidated. To investigate the metabolic traits that underlie the distortion of glucagon secretion under insulin deficient conditions, we generated an αTC1-6 cell line with stable knockdown of the insulin receptor (IRKD), i.e., an in vitro α-cell model for insulin-deficient diabetes, which exhibits an abnormal glucagon response to glucose. A comprehensive metabolomic analysis of the IRKD αTC1-6 cells (IRKD cells) revealed some candidate metabolites whose levels differed markedly compared to those in control αTC1-6 cells, but also which could affect the glucagon release in IRKD cells. Of these candidates, taurine was remarkably increased in the IRKD cells and was identified as a stimulator of glucagon in αTC1-6 cells. Taurine also paradoxically exaggerated the glucagon secretion at a high glucose concentration in IRKD cells and islets with IRKD. These results indicate that the metabolic alterations induced by IRKD in α-cells, especially the increase of taurine, may lead to the distorted glucagon response in IRKD cells, suggesting the importance of taurine in the paradoxical glucagon response and the resultant glucose instability in insulin-deficient diabetes.
Department of Internal Medicine (I), Osaka Medical College, Osaka, Japan.
Megumi
M
Bessho
Department of Internal Medicine (I), Osaka Medical College, Osaka, Japan.
Yuko
Y
Murase-Mishiba
Department of Internal Medicine (I), Osaka Medical College, Osaka, Japan; Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Akihisa
A
Imagawa
Department of Internal Medicine (I), Osaka Medical College, Osaka, Japan.
Jungo
J
Terasaki
Department of Internal Medicine (I), Osaka Medical College, Osaka, Japan.
Toshiaki
T
Hanafusa
D000818:Animals; D002460:Cell Line; D003921:Diabetes Mellitus, Experimental / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D003922:Diabetes Mellitus, Type 1 / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D055785:Gene Knockdown Techniques; D005934:Glucagon / Q000235:genetics / Q000378:metabolism*; D050416:Glucagon-Secreting Cells / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D011972:Receptor, Insulin / Q000235:genetics / Q000378:metabolism; D013654:Taurine / Q000633:toxicity*
D013654:Taurine; D005934:Glucagon; D011972:Receptor, Insulin